China-AsiaStocks.com Reports on Healthcare Opportunities in China; Western and Traditional Medicine
Benda Pharmaceutical Capitalizes on Accelerated Healthcare Spending in China and Growing Opportunities for Gendicine® Cancer Treatment
PR9.NET February 04, 2008 - POINT ROBERTS, Wash., Delta B.C., - China-AsiaStocks.com, an investor and industry portal focused on the China-Asia sector within Investorideas.com, reports on the growing Chinese healthcare market opportunities, with focus on featured company, Benda Pharmaceutical Inc.(OTCBB:BPMA). The globalization and blending of western and traditional medicine is a growing trend, prevalent in China but also on the rise in North America.
Benda Pharmaceutical is a China-based pharmaceutical company producing both Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines. The company recently launched a new investor video www.bendapharma.com/video to provide investors insight into the Benda and Gendicine® investment opportunity.
The company video showcases key investment facts, including revenue growth from $15.9 million in 2006, to projected revenue of $56 million in 2008. Healthcare spending in China is anticipated to grow to $323 billion by 2025 and is a driving force in Benda's projections. Recent announcements by the Chinese government to attempt to tighten control of costs for medical services and drugs heighten awareness to the growing issue.
The rapidly growing healthcare market in China, with an aging and more affluent population, will incite new entrants and new technologies. To be competitive, technologies and products will need to prove claims and meet regulatory standards. According to Benda's video, the company's cancer treatment technology is 340% more effective than traditional treatments.
Other public companies capitalizing on the China healthcare opportunity include Beijing Med-Pharm Corporation (Market, News ), a pharmaceutical marketing and distribution company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China.
Linkwell Corporation (Market, News ) develops, manufactures, and distributes disinfectant healthcare products in China, estimated at $6.25 Billion, according to recent press from the company.
Full News: http://www.investorideas.com/Companies/ViewDocument.asp?ID=5264
For investors researching the sector, Investor Ideas China Asia portal offers a growing directory of listed stocks as a reference tool. Visit: http://www.investorideas.com/Companies/China-AsiaStocks/Stocks_List.asp as well as Investor Ideas features a biotech portal and stock directory.
Benda Pharmaceutical Inc. is a Showcase Company on Investor Ideas on both the China- Asia portal and the Biotech portal. Compensation is disclosed in disclaimer below.
About Benda Pharmaceutical, Inc.:
Benda Pharmaceutical, Inc. www.bendapharma.com
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, Middle East and Australia.
InvestorIdeas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp.
For More Information Contact:
Dawn Van Zant 800-665-0411 Email: firstname.lastname@example.org
Source: China-AsiaStocks.com, Benda Pharmaceutical, Inc.
# # #
About ECON Corporate Services
InvestorIdeas.com® - www.InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing news, stock directories and research links. The site covers over thirty industry sectors and global markets, featuring: investor newsletters, Blogs, RSS news feeds, investor conferences and forums, audio interviews and Podcasts and exclusive industry articles and financial columnists.
|Recent News Headlines
|Industry Category of Current Press Release